Comparison of different dose accumulation strategies to estimate organ doses after stereotactic magnetic resonance-guided adaptive radiotherapy

被引:0
作者
Sebastian Regnery
Lukas Leiner
Carolin Buchele
Philipp Hoegen
Elisabetta Sandrini
Thomas Held
Maximilian Deng
Tanja Eichkorn
Carolin Rippke
C. Katharina Renkamp
Laila König
Kristin Lang
Sebastian Adeberg
Jürgen Debus
Sebastian Klüter
Juliane Hörner-Rieber
机构
[1] Heidelberg University Hospital,Department of Radiation Oncology
[2] National Center for Radiation Oncology (NCRO),Clinical Cooperation Unit Radiation Oncology
[3] Heidelberg Institute for Radiation Oncology (HIRO),undefined
[4] National Center for Tumor diseases (NCT),undefined
[5] German Cancer Research Center (DKFZ),undefined
来源
Radiation Oncology | / 18卷
关键词
Stereotactic body Radiotherapy (SABR); Image-guided Radiotherapy (IGRT); MR-guided adaptive radiotherapy; Pulmonary Cancer; Liver Cancer; Deformable image Registration; Dose accumulation;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 193 条
[1]  
Andratschke N(2022)European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus on re-irradiation: definition, reporting, and clinical decision making Lancet Oncol 23 e469-e78
[2]  
Willmann J(1995)Surveillance or Metastasis-Directed therapy for oligometastatic prostate Cancer recurrence: a prospective, randomized, Multicenter Phase II Trial J Clin oncology: official J Am Soc Clin Oncol 13 8-10
[3]  
Appelt AL(2018)Stereotactic ablative radiotherapy for the Comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial J Clin oncology: official J Am Soc Clin Oncol 36 446-53
[4]  
Alyamani N(2020)Outcomes of Observation vs Stereotactic Ablative Radiation for oligometastatic prostate Cancer: the ORIOLE phase 2 Randomized Clinical Trial J Clin oncology: official J Am Soc Clin Oncol 38 2830-8
[5]  
Balermpas P(2020)Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study JAMA Oncol 6 650-9
[6]  
Baumert BG(2016)Local therapy for Oligoprogressive Disease in patients with Advanced Stage non-small-cell Lung Cancer harboring epidermal growth factor receptor mutation Lancet Oncol 17 1672-82
[7]  
Hellman S(2017)Outcomes of extra-cranial stereotactic body radiotherapy for metastatic colorectal cancer: dose and site of metastases matter Clin Lung Cancer 18 e369-e73
[8]  
Weichselbaum RR(2020)Stereotactic radiotherapy for Oligoprogression in Metastatic Renal Cell Cancer Patients receiving tyrosine kinase inhibitor therapy: a phase 2 prospective Multicenter Study Radiotherapy and oncology: journal of the European Society for Therapeutic Radiology and Oncology 142 236-45
[9]  
Oligometastases P(2021)SMART ablation of lymphatic oligometastases in the pelvis and abdomen: clinical and dosimetry outcomes Eur Urol 80 693-700
[10]  
Ost D(2022)Pattern of progression after stereotactic body radiotherapy for oligometastatic prostate Cancer nodal recurrences Radiotherapy and oncology: journal of the European Society for Therapeutic Radiology and Oncology 168 106-12